(ARCT) Arcturus Therapeutics - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 225m USD | Total Return: -38.7% in 12m

mRNA Vaccines, Rare Disease Therapeutics, Delivery Systems, RNA Medicines
Total Rating 19
Safety 48
Buy Signal -0.82
Biotechnology
Industry Rotation: -6.9
Market Cap: 225M
Avg Turnover: 3.52M
Risk 3d forecast
Volatility76.6%
VaR 5th Pctl12.6%
VaR vs Median-0.46%
Reward TTM
Sharpe Ratio-0.05
Rel. Str. IBD9.4
Rel. Str. Peer Group9
Character TTM
Beta2.234
Beta Downside2.897
Hurst Exponent0.549
Drawdowns 3y
Max DD86.71%
CAGR/Max DD-0.42
CAGR/Mean DD-0.69
EPS (Earnings per Share) EPS (Earnings per Share) of ARCT over the last years for every Quarter: "2021-06": -2.07, "2021-09": -2.05, "2021-12": -1.47, "2022-03": -1.94, "2022-06": -0.82, "2022-09": -1.33, "2022-12": 4.43, "2023-03": 1.87, "2023-06": -1.98, "2023-09": -0.61, "2023-12": -0.32, "2024-03": -1, "2024-06": -0.64, "2024-09": -0.26, "2024-12": -1.11, "2025-03": -0.52, "2025-06": -0.34, "2025-09": -0.49, "2025-12": -1.03, "2026-03": -0.95,
Last SUE: 0.02
Qual. Beats: 0
Revenue Revenue of ARCT over the last years for every Quarter: 2021-06: 2.001, 2021-09: 2.437, 2021-12: 5.794, 2022-03: 5.244, 2022-06: 27.093, 2022-09: 13.369, 2022-12: 160.293, 2023-03: 80.285, 2023-06: 10.519, 2023-09: 43.376, 2023-12: 25.078, 2024-03: 32.598, 2024-06: 45.976, 2024-09: 38.815, 2024-12: 21, 2025-03: 29.382, 2025-06: 24.51, 2025-09: 17.151, 2025-12: 3.081, 2026-03: 0.61,
Rev. CAGR: -39.42%
Rev. Trend: -89.1%
Last SUE: -0.32
Qual. Beats: 0

Warnings

Interest Coverage Ratio -8407.2 is critical

Altman Z'' -0.36 < 1.0 - financial distress zone

Below Avwap Earnings

Tailwinds

No distinct edge detected

Description: ARCT Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc. is a clinical-stage biotechnology company specializing in messenger RNA (mRNA) medicines for rare respiratory and liver diseases. The company utilizes two proprietary technology platforms: STARR, a self-amplifying mRNA system, and LUNAR, a lipid-mediated delivery vehicle designed to transport genetic material into target cells.

The current pipeline includes mRNA therapeutic candidates for cystic fibrosis (ARCT-032) and ornithine transcarbamylase deficiency (ARCT-810), both of which are in Phase 2 clinical trials. The company also develops vaccine candidates for COVID-19, seasonal influenza, and pandemic influenza (H5N1). In the biotechnology sector, mRNA-based firms often rely on strategic partnerships and intellectual property licensing to fund the high capital expenditures required for multi-phase clinical testing.

Investors should evaluate the firms clinical trial milestones alongside the valuation metrics available on ValueRay. Headquartered in San Diego, Arcturus focuses on the high-growth genomic medicine market, where delivery efficiency remains a primary competitive differentiator.

Headlines to Watch Out For
  • Commercial uptake of KOSTAIVE mRNA vaccine drives near-term revenue and royalty streams
  • Phase 2 clinical data for ARCT-032 dictates cystic fibrosis program valuation
  • Strategic collaboration milestones with CSL impact cash runway and operational funding
  • Regulatory progress of LUNAR-OTC influences expansion into rare liver disease markets
  • Adoption of self-amplifying mRNA technology platform determines long-term licensing potential
Piotroski VR-10 (Strict) 0.0
Net Income: -78.7m TTM > 0 and > 6% of Revenue
FCF/TA: -0.24 > 0.02 and ΔFCF/TA 3.09 > 1.0
NWC/Revenue: 402.4% < 20% (prev 169.7%; Δ 232.7% < -1%)
CFO/TA -0.24 > 3% & CFO -58.6m > Net Income -78.7m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 6.31 > 1.5 & < 3
Outstanding Shares: last quarter (28.4m) vs 12m ago 4.85% < -2%
Gross Margin: 93.33% > 18% (prev 97.38%; Δ -4.05% > 0.5%)
Asset Turnover: 15.71% > 50% (prev 40.74%; Δ -25.03% > 0%)
Interest Coverage Ratio: -8.41k > 6 (EBIT TTM -75.7m / Interest Expense TTM 9.00k)
Altman Z'' -0.36
A: 0.74 (Total Current Assets 216.9m - Total Current Liabilities 34.4m) / Total Assets 245.4m
B: -2.21 (Retained Earnings -541.6m / Total Assets 245.4m)
C: -0.26 (EBIT TTM -75.7m / Avg Total Assets 288.6m)
D: 3.54 (Book Value of Equity 191.4m / Total Liabilities 54.0m)
Altman-Z'' = -0.36 = B
Beneish M -4.00
DSRI: 0.27 (Receivables 1.34m/14.6m, Revenue 45.4m/135.2m)
GMI: 1.04 (GM 97.38% / 93.33%)
AQI: 0.15 (AQ_t 0.01 / AQ_t-1 0.06)
SGI: 0.34 (Revenue 45.4m / 135.2m)
TATA: -0.08 (NI -78.7m - CFO -58.6m) / TA 245.4m)
Beneish M = -4.57 (Cap -4..+1) = AAA
What is the price of ARCT shares?

As of June 06, 2026, the stock is trading at USD 7.30 with a total of 411,628 shares traded.
Over the past week, the price has changed by -7.83%, over one month by -13.20%, over three months by +0.69% and over the past year by -38.71%.

Is ARCT a buy, sell or hold?

Arcturus Therapeutics has received a consensus analysts rating of 4.73. Therefore, it is recommended to buy ARCT.

  • StrongBuy: 8
  • Buy: 3
  • Hold: 0
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the ARCT price?
Analysts Target Price 19.9 172.5%
Arcturus Therapeutics (ARCT) - Fundamental Data Overview as of 30 May 2026
Market Cap USD = 225.1m (225.1m USD * 1.0 USD.USD)
P/E Forward = 2.4777
P/S = 4.1147
P/B = 1.137
Revenue TTM = 45.4m USD
EBIT TTM = -75.7m USD
EBITDA TTM = -72.8m USD
 Long Term Debt = unknown (none)
 Short Term Debt = 4.21m USD (from shortTermDebt, last fiscal year)
Debt = 43.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 24.0m
Net Debt = -167.7m USD (calculated: Debt 43.7m - CCE 211.4m)
Enterprise Value = 57.4m USD (225.1m + Debt 43.7m - CCE 211.4m)
Interest Coverage Ratio = -8.41k (Ebit TTM -75.7m / Interest Expense TTM 9.00k)
EV/FCF = -0.97x (Enterprise Value 57.4m / FCF TTM -58.9m)
 FCF Yield = -102.6% (FCF TTM -58.9m / Enterprise Value 57.4m)
 FCF Margin = -129.9% (FCF TTM -58.9m / Revenue TTM 45.4m)
 Net Margin = -173.5% (Net Income TTM -78.7m / Revenue TTM 45.4m)
Gross Margin = 93.33% ((Revenue TTM 45.4m - Cost of Revenue TTM 3.02m) / Revenue TTM)
Gross Margin QoQ = -7.87% (prev 77.86%)
Tobins Q-Ratio = 0.23 (Enterprise Value 57.4m / Total Assets 245.4m)
Interest Expense / Debt = 0.02% (Interest Expense 9.00k / Debt 43.7m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -59.8m (EBIT -75.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.31 (Total Current Assets 216.9m / Total Current Liabilities 34.4m)
Debt / Equity = 0.23 (Debt 43.7m / totalStockholderEquity, last quarter 191.4m)
 Debt / EBITDA = 2.30 (negative EBITDA) (Net Debt -167.7m / EBITDA -72.8m)
 Debt / FCF = 2.85 (negative FCF - burning cash) (Net Debt -167.7m / FCF TTM -58.9m)
 Total Stockholder Equity = 215.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -27.26% (Net Income -78.7m / Total Assets 245.4m)
RoE = -36.55% (Net Income TTM -78.7m / Total Stockholder Equity 215.2m)
RoCE = -35.85% (EBIT -75.7m / Capital Employed (Total Assets 245.4m - Current Liab 34.4m))
 RoIC = -28.07% (negative operating profit) (NOPAT -59.8m / Invested Capital 213.0m)
 WACC = 11.59% (E(225.1m)/V(268.8m) * Re(13.84%) + D(43.7m)/V(268.8m) * Rd(0.02%) * (1-Tc(0.21)))
Discount Rate = 13.84% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 95.56 | Cagr: 2.94%
 [DCF] Fair Price = unknown (Cash Flow -58.9m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.02 | # QB: 0
Revenue Correlation: -89.15 | Revenue CAGR: -39.42% | SUE: -0.32 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-1.03 | Chg30d=+0.07% | Revisions=+29% | Analysts=10
EPS next Quarter (2026-09-30): EPS=-0.88 | Chg30d=+11.62% | Revisions=+23% | Analysts=10
EPS current Year (2026-12-31): EPS=-3.87 | Chg30d=+3.93% | Revisions=-8% | GrowthEPS=-61.1% | GrowthRev=-71.8%
EPS next Year (2027-12-31): EPS=-3.99 | Chg30d=+5.14% | Revisions=+17% | GrowthEPS=-3.2% | GrowthRev=+52.4%
[Analyst] Revisions Ratio: +29%